Date | Title | Description | Source |
13.11.2023 | aTyr Pharma Presents Poster Demonstrating Preclinical Effect... | Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibros... | einpresswi... |
09.08.2023 | aTyr Pharma Announces Second Quarter 2023 Results and Provid... | Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Eur... | einpresswi... |
22.05.2023 | aTyr Pharma Presents New Data on Efzofitimod Mechanism of Ac... | /EIN News/ -- Advancement in mechanistic understanding of efzofitimod’s modulation of myeloid cells ... | einpresswi... |
06.02.2023 | aTyr Pharma Announces Achievement of Development Milestone b... | /EIN News/ -- $10M milestone payment triggered by advancement of clinical program in Japan.
Multipl... | einpresswi... |
18.11.2022 | aTyr Pharma Announces Inducement Grants Under Nasdaq Listing... | /EIN News/ -- SAN DIEGO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a bioth... | einpresswi... |
25.10.2022 | aTyr Pharma to Present at the Jefferies London Healthcare Co... | /EIN News/ -- SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a bioth... | einpresswi... |
25.10.2022 | aTyr Pharma to Present at the Jefferies London Healthcare Co... | SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com... | globenewsw... |
13.09.2022 | aTyr Pharma Receives FDA Fast Track Designation for Efzofiti... | /EIN News/ -- Second Fast Track designation for efzofitimod clinical program.
Efzofitimod previousl... | einpresswi... |
13.09.2022 | aTyr Pharma Receives FDA Fast Track Designation for Efzofiti... | Second Fast Track designation for efzofitimod clinical program.
Efzofitimod previously received FDA... | globenewsw... |
09.09.2022 | aTyr Pharma to Present at the Life Sciences Investor Forum o... | SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (the “Company”), a bi... | globenewsw... |
01.09.2022 | aTyr Pharma to Present Poster at the European Respiratory So... | SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics co... | globenewsw... |
15.08.2022 | aTyr Pharma Announces Second Quarter 2022 Results and Provid... | First sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis.
FDA grante... | globenewsw... |
11.08.2022 | aTyr Pharma Receives FDA Fast Track Designation for Efzofiti... | SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”... | globenewsw... |
14.06.2022 | aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA... | Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair.
Second tRNA syntheta... | globenewsw... |
13.06.2022 | aTyr Pharma to Present Findings from its tRNA Synthetase Pla... | SAN DIEGO, June 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com... | globenewsw... |
01.06.2022 | aTyr Pharma to Present at the 2022 Jefferies Healthcare Conf... | SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com... | globenewsw... |
16.05.2022 | aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923... | Global pivotal EFZO-FIT™ study expected to begin in the third quarter of 2022
Primary endpoint will... | globenewsw... |
13.05.2022 | aTyr Pharma Announces Inducement Grants Under Nasdaq Listing... | SAN DIEGO, May 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics comp... | globenewsw... |
09.05.2022 | aTyr Pharma Announces First Quarter 2022 Results and Provide... | Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming Ame... | globenewsw... |
01.04.2022 | aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR19... | Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety a... | globenewsw... |
23.02.2022 | aTyr Pharma to Participate in Panel at National Institutes o... | SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com... | globenewsw... |
07.02.2022 | aTyr Pharma to Present at BIO CEO & Investor Conference | SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com... | globenewsw... |
06.01.2022 | ATyr Pharma Announces FDA Orphan Drug Designation for ATYR19... | SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biot... | marketscre... |
04.01.2022 | aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect... | SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com... | globenewsw... |
24.12.2021 | ATyr Pharma Appoints Danielle Campbell as Vice President of ... | SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com... | marketscre... |
10.12.2021 | ATyr Pharma to Present at Antibody Engineering & Therape... | SAN DIEGO, Dec. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com... | marketscre... |
12.11.2021 | aTyr Pharma to Present at Upcoming Investor Conferences in N... | SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com... | globenewsw... |
11.11.2021 | ATyr Pharma Announces Third Quarter 2021 Results and Provide... | aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update
Positive results rep... | marketscre... |
11.11.2021 | ATyr Pharma Announces Third Quarter 2021 Results and Provide... | Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provi... | marketscre... |
10.11.2021 | aTyr Pharma Announces Third Quarter 2021 Results and Provide... | Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provi... | globenewsw... |
09.11.2021 | ATyr Pharma Presents Research Demonstrating Effects of Novel... | Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to mo... | marketscre... |
06.10.2021 | aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD... | SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com... | globenewsw... |
06.10.2021 | ATyr Pharma : Announces Appointment of Robert W. Ashworth, P... | SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com... | marketscre... |
01.10.2021 | ATyr Pharma : Announces Poster Presentation at the Society f... | SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com... | marketscre... |
20.09.2021 | aTyr Pharma Announces Closing of $86.3 Million Public Offeri... | SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage bio... | marketscre... |
16.09.2021 | ATyr Pharma : Announces Pricing of $75 Million Public Offeri... | SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage bio... | marketscre... |
13.09.2021 | ATyr Pharma : Announces Positive Data from Phase 1b/2a Clini... | aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Re... | marketscre... |
13.09.2021 | aTyr Pharma Announces Positive Data from Phase 1b/2a Clinica... | Trial met primary endpoint, ATYR1923 was safe and well-tolerated.
Efficacy observed in key endpoint... | marketscre... |
10.08.2021 | ATyr Pharma : Announces Expansion of Research Collaboration ... | Collaboration led by Dr.
Elliott Crouser to explore underlying cellular mechanisms of pulmonary sar... | marketscre... |
10.08.2021 | ATyr Pharma : Announces Second Quarter 2021 Results and Prov... | Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September ... | marketscre... |
10.08.2021 | ATyr Pharma : Announces Second Quarter 2021 Results and Prov... | aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update
Data from Phase 1b/... | marketscre... |
09.08.2021 | ATyr Pharma : Announces Two Abstracts for ATYR1923 Accepted ... | SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com... | marketscre... |
29.07.2021 | ATyr Pharma : Announces Grant of U.S. Patent for Use of Hist... | SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com... | marketscre... |
08.07.2021 | aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clin... | Results from proof-of-concept study are expected in September 2021.
SAN DIEGO, July 08, 2021 (GLOBE... | marketscre... |
23.06.2021 | ATyr Pharma : to Host Virtual Key Opinion Leader Event on Cu... | Event will feature Dr.
Daniel Culver, Director of the Interstitial Lung Disease Program at the Clev... | marketscre... |
10.06.2021 | ATYR PHARMA, INC.
aTyr Pharma Presents Poster Demonstrating... | Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of ant... | marketscre... |
25.05.2021 | ATYR PHARMA, INC.
ATyr Pharma : Strengthens Board of Direct... | SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics comp... | marketscre... |
25.05.2021 | ATYR PHARMA, INC.
ATyr Pharma : Strengthens Board of Direct... | aTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen
SAN DIEGO - May 25,... | marketscre... |
19.05.2021 | ATYR PHARMA, INC.
ATyr Pharma : Presents Preclinical Resear... | SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics comp... | marketscre... |
13.05.2021 | ATYR PHARMA, INC.
ATyr Pharma : Announces First Quarter 202... | Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quar... | marketscre... |
13.05.2021 | ATyr Pharma : Announces First Quarter 2021 Results and Provi... | Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quar... | marketscre... |
12.05.2021 | ATYR PHARMA, INC.
ATyr Pharma : and its Hong Kong Subsidiar... | SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics comp... | marketscre... |
11.05.2021 | ATYR PHARMA, INC.
ATyr Pharma : Announces Promotion of Lesl... | SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics comp... | marketscre... |
20.04.2021 | ATYR PHARMA, INC.
ATyr Pharma : and Foundation for Sarcoido... | SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics co... | marketscre... |
15.04.2021 | ATYR PHARMA, INC.
ATyr Pharma : and Lonza Announce Manufact... | Basel, Switzerland, and San Diego, USA - aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company... | marketscre... |
14.04.2021 | ATYR PHARMA, INC.
ATyr Pharma : and Lonza Announce Manufact... | SAN DIEGO, April 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics co... | marketscre... |
08.04.2021 | ATYR PHARMA, INC.
aTyr Pharma Announces Co-Founder of the F... | SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics co... | marketscre... |
23.03.2021 | ATYR PHARMA, INC.
ATyr Pharma : Announces Fourth Quarter an... | Completed enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. Data is expe... | marketscre... |
23.03.2021 | ATyr Pharma : Announces Fourth Quarter and Full Year 2020 Re... | Completed enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. Data is expe... | marketscre... |
11.03.2021 | aTyr Pharma Announces Poster Presentations at the American A... | SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics co... | globenewsw... |
10.03.2021 | Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharm... | SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics co... | globenewsw... |
25.02.2021 | aTyr Pharma to Present at March Investor Conferences | SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com... | globenewsw... |
21.11.2016 |
aTyr Pharma Gets $20M Credit Facility
| San Diego-based biotherapeutics developer aTyr Pharma announced this morning that it has received a ... | socaltech.... |
29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
03.05.2015 | ATyr Pharma Plans to Raise Approximately $76M in IPO | ATyr Pharma Inc. is planning to raise approximately $76 million in an IPO May 7th. The company will ... | sdbj.com/n... |
01.04.2015 | aTyr Pharma Completes $76M Series E Financing | aTyr Pharma, Inc., a San Diego, CA-based biotherapeutics company engaged in the discovery and develo... | finsmes.co... |
01.04.2015 | aTyr raised a $76M Series E. So when’s that IPO? | Another sign for pending IPO – large institutional investors.
The startup’s using the funding to ad... | medcitynew... |
01.04.2015 | aTyr Pharma Secures $76M in Series E |
SAN DIEGO, CA, Biotherapeutics company engaged in the discovery and development of Physiocrine-bas... | vcnewsdail... |
01.04.2015 |
aTyr Pharma Finds $76M
| San Diego-based biopharmaceuticals developer aTyr Pharma has raised a big, $76M Series E funding rou... | socaltech.... |
31.03.2015 | aTyr Pharma Secures $76 Million in Series E Financing |
SAN DIEGO--(BUSINESS WIRE)--aTyr Pharma, Inc. (“aTyr”), a biotherapeutics company engaged in the... | domainvc.c... |
29.07.2013 |
aTyr Pharma Gets $10M In Venture Debt
| San Diego-based aTyr Pharma, a developer of protein-based therapeutics, said today that it has raise... | socaltech.... |
29.07.2013 | aTyr Pharma Closes $10M Venture Debt |
SAN DIEGO, CA, Innovative protein therapeutics enterprise focused on rare diseases, announced toda... | vcnewsdail... |
29.07.2013 | aTyr Pharma Completes $49M Equity Financing | aTyr Pharma, a San Diego CA-based protein therapeutics enterprise focused on rare diseases, complete... | finsmes.co... |
29.07.2013 | aTyr Pharma Closes $10 Million Venture Debt Loan from Silico... |
SAN DIEGO, July 29, 2013 /PRNewswire/ -- aTyr Pharma, an innovative protein therapeutics enterpr... | domainvc.c... |
29.07.2013 | aTyr Pharma Completes $49 Million Financing to Advance a The... |
SAN DIEGO, July 29, 2013 /PRNewswire/ -- aTyr Pharma, an innovative protein therapeutics enterpr... | domainvc.c... |
26.10.2010 |
aTyr Pharma Nabs $23M
| San Diego-based aTyr Pharma, a developer of biotherapeutics aimed at the blood, immune, and metaboli... | socaltech.... |
26.10.2010 | aTyr Pharma Raises $23M in Series C Financing | aTyr Pharma, a San Diego CA-based company that develops biologic therapeutics based on physiocrine, ... | finsmes.co... |
29.07.2009 | aTyr Pharma raises $12m for research | The company is discovering and developing biotherapeutics to treat a wide variety of diseases includ... | altassets.... |
28.07.2009 |
aTyr Pharma Gets $12M
| San Diego-based aTyr Pharma, which is developing biopharmaceuticals focused on inflammation, autoimm... | socaltech.... |
18.04.2007 |
aTyr Pharma Raises $10.5M
| San Diego-based aTyr Pharma, a biopharmaceutical firm focused on protein biologics for human therape... | socaltech.... |
- | aTyr raised a $76M Series E. So when’s that IPO? | San Diego biotech aTyr Pharma just closed out an impressive $76 million, with a large chunk of it pu... | medcitynew... |